Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

3.

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U; Eastern Cooperative Oncology Group.

Clin Cancer Res. 2004 Mar 1;10(5):1670-7.

4.

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH.

J Clin Oncol. 1996 Jan;14(1):7-17.

PMID:
8558223
5.

Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS.

J Clin Oncol. 2007 Mar 1;25(7):869-75.

PMID:
17327608
7.

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.

Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N.

Cancer. 1996 Apr 1;77(7):1303-10.

8.

Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes.

Grotz TE, Vaince F, Hieken TJ.

Melanoma Res. 2013 Apr;23(2):132-7. doi: 10.1097/CMR.0b013e32835e5880.

PMID:
23344159
9.

Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients.

Tas F, Erturk K.

Cancer Invest. 2017 Sep 14;35(8):501-505. doi: 10.1080/07357907.2017.1351984. Epub 2017 Aug 11.

PMID:
28799813
10.

Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F.

Hum Pathol. 2016 Nov;57:116-125. doi: 10.1016/j.humpath.2016.07.008. Epub 2016 Jul 26. Erratum in: Hum Pathol. 2017 May;63:222.

11.

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Mandalà M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, Marchesi L, Poletti P, Bonomi L, Novellino L, Di Biagio K, Milesi A, Guerra U, Tondini C.

Eur J Cancer. 2009 Sep;45(14):2537-45. doi: 10.1016/j.ejca.2009.05.034. Epub 2009 Jun 22.

PMID:
19553103
12.

Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.

Fortes C, Mastroeni S, Mannooranparampil TJ, Passarelli F, Zappalà A, Annessi G, Marino C, Caggiati A, Russo N, Michelozzi P.

Melanoma Res. 2015 Aug;25(4):306-11. doi: 10.1097/CMR.0000000000000164.

PMID:
25933208
13.

Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.

Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF.

J Clin Oncol. 2012 Jul 20;30(21):2678-83. doi: 10.1200/JCO.2011.37.8539. Epub 2012 Jun 18.

PMID:
22711850
14.

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH.

J Clin Oncol. 2000 Jun;18(12):2444-58.

PMID:
10856105
15.

99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study.

Signore A, Annovazzi A, Barone R, Bonanno E, D'Alessandria C, Chianelli M, Mather SJ, Bottoni U, Panetta C, Innocenzi D, Scopinaro F, Calvieri S.

J Nucl Med. 2004 Oct;45(10):1647-52.

16.

Tumor-infiltrating lymphocytes and their significance in melanoma prognosis.

Schatton T, Scolyer RA, Thompson JF, Mihm MC Jr.

Methods Mol Biol. 2014;1102:287-324. doi: 10.1007/978-1-62703-727-3_16. Review.

PMID:
24258985
17.
18.

CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma.

Fujii H, Arakawa A, Utsumi D, Sumiyoshi S, Yamamoto Y, Kitoh A, Ono M, Matsumura Y, Kato M, Konishi K, Shiga T, Sano S, Sakaguchi S, Miyagawa-Hayashino A, Takahashi K, Uezato H, Miyachi Y, Tanioka M.

Int J Cancer. 2014 May 15;134(10):2393-402. doi: 10.1002/ijc.28581. Epub 2013 Nov 18.

19.

Prognostic impact of B-cell density in cutaneous melanoma.

Ladányi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejös Z, Gaudi I, Dobos J, Tímár J.

Cancer Immunol Immunother. 2011 Dec;60(12):1729-38. doi: 10.1007/s00262-011-1071-x. Epub 2011 Jul 21.

PMID:
21779876
20.

Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study.

Reali UM, Martini L, Borgognoni L, Semino C, Pietra G, Chiarugi C, Guastella M, Melioli G.

Melanoma Res. 1998 Feb;8(1):77-82.

PMID:
9508381

Supplemental Content

Support Center